CN1655810A - 高尿酸血症治疗或预防用组合物 - Google Patents
高尿酸血症治疗或预防用组合物 Download PDFInfo
- Publication number
- CN1655810A CN1655810A CNA03811691XA CN03811691A CN1655810A CN 1655810 A CN1655810 A CN 1655810A CN A03811691X A CNA03811691X A CN A03811691XA CN 03811691 A CN03811691 A CN 03811691A CN 1655810 A CN1655810 A CN 1655810A
- Authority
- CN
- China
- Prior art keywords
- chondroitin sulfate
- albumen composition
- food
- described compositions
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 20
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 56
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 56
- 201000005569 Gout Diseases 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims description 38
- 230000002265 prevention Effects 0.000 claims description 14
- 210000000845 cartilage Anatomy 0.000 claims description 12
- 241000251468 Actinopterygii Species 0.000 claims description 6
- 238000007670 refining Methods 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241000270322 Lepidosauria Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000237852 Mollusca Species 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 239000012491 analyte Substances 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 235000015170 shellfish Nutrition 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 35
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 31
- 229940116269 uric acid Drugs 0.000 abstract description 31
- 210000002966 serum Anatomy 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 description 23
- 229920002683 Glycosaminoglycan Polymers 0.000 description 14
- 239000002994 raw material Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- 241000251730 Chondrichthyes Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 3
- 241000209051 Saccharum Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000021438 curry Nutrition 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 229950000193 oteracil Drugs 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000012622 synthetic inhibitor Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004186 food analysis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000186652 Sporosarcina ureae Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- XIKIPZDTTJQYGT-UHFFFAOYSA-L calcium;6,8-dioxo-7,9-dihydro-3h-purin-2-olate Chemical compound [Ca+2].N1C([O-])=NC(=O)C2=C1NC(=O)N2.N1C([O-])=NC(=O)C2=C1NC(=O)N2 XIKIPZDTTJQYGT-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000019503 curry powder Nutrition 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013890 disodium inosinate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940080428 lactose 200 mg Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/06—Meat products; Meat meal; Preparation or treatment thereof with gravy or sauce
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L23/00—Soups; Sauces; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/28—Substances of animal origin, e.g. gelatin or collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
本发明涉及含有硫酸软骨素蛋白复合物作为有效成分的高尿酸血症治疗或预防用组合物。该高尿酸血症治疗或预防用组合物具有降低血清尿酸值的作用,特别是使治疗痛风、预防及减少痛风发作的新的方法成为可能。
Description
技术领域
本发明涉及具有降低血清尿酸值的作用的高尿酸血症治疗或预防用组合物。
背景技术
随着近年来饮食生活水平的提高,痛风已成为严重的生活习惯病。已知痛风是由于体内产生的过剩的尿酸在手足指(趾)等部位作为尿酸钙沉着而引起的,突然地产生剧痛。痛风的治疗如下进行:①使用尿酸合成抑制剂,以抑制体内的尿酸蓄积;及②使用尿酸排泄促进剂和尿碱化剂,以迅速排泄体内蓄积的尿酸。
现在,作为容易得到的尿酸合成抑制剂例如有别嘌醇。作为尿酸排泄促进剂,已知有丙磺舒、苯磺唑酮、苯溴马隆。但是,已知别嘌醇有发生皮疹、中毒综合征、骨髓抑制、肝损害等全身性过敏症状等副作用,其使用上要求十分谨慎。另外,苯溴马隆等尿酸排泄促进剂,如果使用方法错误反而有导致痛风发作等的问题。
硫酸软骨素是代表性的硫酸化粘多糖,根据O-硫酸基的位置和数目存在A~K亚型。据报导,软骨中存在硫酸软骨素A、C,皮肤中存在硫酸软骨素B。也包括下述硫酸基的含有率高的硫酸软骨素:鲨鱼软骨中的硫酸软骨素D、鱿鱼软骨中的硫酸软骨素E、鲎鱼软骨中的硫酸软骨素K(参照东京化学同人出版的生化学事典第3版第556页硫酸软骨素项)。
硫酸软骨素在正常的生物体内不以游离的状态存在,而是作为与蛋白质结合的粘多糖蛋白质(蛋白多糖)存在,发挥其功能(参照NewFood Industry,vol.41,No.9,1999)。蛋白多糖主要分布在软骨、皮肤、腱、韧带、骨等中,其中软骨中含的特别多(参照New FoodIndustry,vol.40,No.2,1998)。
其生理功能为构成高分子基质以维持实质细胞,构建各器官的特定构造(参照New Food Industry,vol.41,No.9,1999)。其他还有保水性非常大,参与通过生物体内的水分进行的营养输送、吸收(参照New Food Industry,vol.31,No.9,1989)。从近年来生化研究的进步及包括动物实验的临床试验的经验看,作为代表性的特征例如有10项:调节体内水分量、促进骨形成、润滑关节、改善血脂、调节血管新生、调节进出细胞的物质、快速治疗创伤、防止细菌感染、抑制血液凝固、维持眼睛透明度(参照New Food Industry,vol.41,No.9,1999)。
例如,本申请的申请人公开了:钙或将其含有物换算成钙每3重量份添加20~80重量份硫酸软骨素蛋白复合物的饲料,或不添加硫酸软骨素蛋白复合物的饲料,让诱导了骨质疏松症的大鼠摄取,结果,硫酸软骨素蛋白复合物摄取组与硫酸软骨素蛋白复合物非摄取组相比,促进了钙吸收,骨强度增加(参照专利第3248170号公报)。
发明内容
本发明的目的是提供具有降低血清尿酸值的作用,特别是使治疗痛风、预防及减少痛风发作的新的方法成为可能的新型高尿酸血症治疗或预防用组合物。
本发明人等为达成上述目的进行了各种研究,结果发现硫酸软骨素蛋白复合物降低血清尿酸值。
本发明是基于上述发现而完成的,提供含有硫酸软骨素蛋白复合物作为有效成分的高尿酸血症治疗或预防用组合物。
另外,本发明提供含有硫酸软骨素蛋白复合物的食品,其特征是添加上述本发明的高尿酸血症治疗或预防用组合物,使硫酸软骨素蛋白复合物的含量达到10mg~5g的范围。
由于痛风发作时尿酸内环境稳定机制发生异常,本发明的组合物的有效成分硫酸软骨素蛋白复合物降低血清尿酸值,通过使用本发明的组合物,开辟了与以往使用尿酸合成抑制剂和使用尿酸排泄促进剂不同的、治疗痛风、预防及减少痛风发作的症状的新的方法的可能性。
附图说明
图1是后述实验例2中研究高尿酸血症诱导物质摄食组和高尿酸血症诱导物质+SCP摄食组的血清尿酸值的变动的图。
图2是后述实验例2中研究高尿酸血症诱导物质摄食组和摄食开始第29天从摄食高尿酸血症诱导物质换成摄食高尿酸血症诱导物质+SCP组的血清尿酸值的变动的图。
图3是后述实验例3中比较28天摄取试验食物后的血清尿酸值的图。
图4是表示硫酸软骨素蛋白复合物的制备工艺的流程图。
具体实施方式
下面详细说明本发明的高尿酸血症治疗或预防用组合物的优选的实施方式。
本发明的组合物的有效成分硫酸软骨素蛋白复合物来自天然物,是通常吃的食品中的一种成分,所以其安全性没有问题。作为上述硫酸软骨素蛋白复合物,例如来自软骨鱼类、硬骨鱼类、哺乳类、鸟类、爬虫类、两栖类、甲壳类或软体动物,其中优选来自软骨鱼类。
本发明使用的硫酸软骨素蛋白复合物,按照图4的流程图所示的步骤制备。即,以软骨为原料时,将鲨鱼、牛等的软骨用蛋白酶消化后,精制消化物(过滤、活性炭处理),根据需要喷雾干燥制备而成。另外,将软骨用热水提取后或将软骨用盐酸等酸分解后,精制提取物或分解物(过滤、活性炭处理),根据需要喷雾干燥制备而成。这样的硫酸软骨素蛋白复合物,例如有市售的SCP、SCP(NB)(以上由Maruha株式会社生产)、软骨素Q(20%)(QP株式会社生产)、SNC(Nichiro株式会社生产)、硫酸软骨素(食品用)(新日本药业株式会社生产)、硫酸软骨素(烟台东诚生化有限公司生产)、PCS-20(Pacific公司生产)等,本发明中也可以使用这些市售品。
作为本发明使用的硫酸软骨素蛋白复合物,按硫酸钡重量法测定粘多糖时,优选含有粘多糖15质量%以上,特别优选含有30质量%以上;按财团法人日本健康·营养食品协会粘多糖·蛋白食品规格基准的粘多糖·蛋白的含量测定法咔唑硫酸法测定时,优选含有粘多糖6质量%以上,特别优选含有13质量%以上。另外,本发明使用的硫酸软骨素蛋白复合物,关于蛋白质,按财团法人日本健康·营养食品协会粘多糖·蛋白食品规格基准的粘多糖·蛋白的含量测定法半微量凯氏定氮法测定时,优选含有蛋白质4质量%以上,特别优选含有20质量%以上。而且,本发明使用的硫酸软骨素蛋白复合物,pH优选为4.0~8.0,特别优选为5.5~7.0;干燥失重优选为20.0质量%以下,特别优选为10.0质量%以下;炽灼残渣(灰分)优选为1.0~20.0质量%,特别优选为5.0~20.0质量%;脂质的含量优选为5.0质量%以下,特别优选为1.0质量%以下。
本发明的组合物中,除上述硫酸软骨素蛋白复合物外,根据需要,也可以含有糖类或盐等等渗剂、使具有适应生物体内pH的pH缓冲剂、表面活性剂、抗氧剂、吸收延迟剂等。
本发明的组合物,例如可以使用乳糖、白土、蔗糖、糊精、滑石、明胶、琼脂、果胶、阿拉伯胶、硬脂酸镁等适当的固体载体,作成片剂、散剂、颗粒剂、锭剂(troch)或胶囊剂,或适当使用糖浆、檀物油、水等液体载体,作成糖浆、软胶囊剂和饮料剂,通过口服摄取。
另外,本发明的组合物,也可以以添加到其他食品中的形式摄取,对应于目的物食品的形状,以任何形式添加效果也不变。因此,可以应用于许多食品。例如,主食面包、法国面包、奶油盘肠面包(butterroll)、奶昔、玉米浓汤、法国浓汤(potage soap)、咖喱饭、炖肉等。
本发明的组合物中硫酸软骨素蛋白复合物的含量,可以以下述硫酸软骨素蛋白复合物的有效量为标准,考虑一日的服用次数和用量来确定。
另外,将本发明的组合物添加到其他食品中时,也可以以下述硫酸软骨素蛋白复合物的有效量为标准,确定其添加量。
硫酸软骨素蛋白复合物的有效量,需要降低血清尿酸值的成人每日,以精制物计,优选为10mg~5g,更加优选为150mg~1g,一日分1次~数次摄取。但是,这里所示的每日的摄取量只是作为标准表示的量,具体的摄取量还应根据摄取者的年龄、体重、性别、症状、其他状况来确定。通常,所说的需要降低血清尿酸值的场合,是指痛风发作的场合,或者吃饭或饮酒前、正在吃饭或饮酒、吃饭或饮酒后不久这些预料有痛风发作危险性的场合。另外,血清尿酸值超过7.0mg/dl时,认为也有必要采取某些措施来降低其值。
下面列举表示本发明的效果的实验例及实施例,可是,这些实验例及实施例对本发明并没有任何限制。
实验例1
给7周龄SD雌性大鼠(n=5,共10只)胃内强制给予来自鲨鱼的硫酸软骨素蛋白复合物(SCP:Maruha株式会社生产)或蒸馏水(对照),上述大鼠每kg体重1g量,给予14天。给予结束后,从腹侧主动脉采取血液,血清化,进行GOT、GPT、总胆固醇、HDL-胆固醇、葡萄糖、总胆红素、总蛋白质、白蛋白、脲氮、肌酸酐、Ca、Na、Cl、碱性磷酸酶(ALP)、尿酸,共15项的生化检查。结果,SCP组尿酸浓度与对照组相比,显示显著低值(p<0.01)。其结果如下述表1所示。
[表1]
对照组 | SCP组 | T检验 | |
总蛋白质(g/dl) | 4.82 | 5.32 | n.s. |
HDL-胆固醇(mg/dl) | 39.0 | 34.0 | n.s. |
白蛋白(g/dl) | 3.22 | 3.16 | n.s. |
总胆红素(mg/dl) | 0.24 | 0.26 | n.s. |
葡萄糖(mg/dl) | 122.0 | 117.0 | n.s. |
总胆固醇(mg/dl) | 70.0 | 53.7 | n.s. |
脲氮(mg/dl) | 20.3 | 21.0 | n.s. |
肌酸酐(mg/dl) | 0.46 | 0.40 | n.s. |
Na(mEq/l) | 128.2 | 123.8 | n.s. |
Cl(mEq/l) | 89.8 | 86.4 | n.s. |
GOT(IU/l/37℃) | 56.6 | 49.6 | n.s. |
GPT(IU/l/37℃) | 16.3 | 17.3 | n.s. |
ALP(KAU) | 548.0 | 557.0 | n.s. |
Ca(mg/100ml) | 9.76 | 9.38 | n.s. |
尿酸(mg/100ml) | 1.13 | 0.47 | p<0.01 |
n.s.:没有显著性差异
实验例2
驯化饲养结束后,使10周龄SD雌性大鼠(n=6,共18只)自由摄取下述饲料:Oriental酵母株式会社生产的Oriental配合饲料中含有总量的2.5质量%的诱导高尿酸血症的氧嗪酸钾(potassium oxonate)的饲料(诱导食物),或该饲料(诱导食物)中进一步含有总量的1.5质量%的来自鲨鱼的硫酸软骨素蛋白复合物(SCP:Maruha株式会社生产)的饲料(诱导+SCP食物)(10~15g/天),跟踪血清尿酸值的变化。实验组设定“诱导食物组”和“诱导食物+SCP组”2组,以及两组间血清尿酸值出现差别时从诱导食物换成诱导+SCP食物的“诱导食物→诱导食物+SCP组”,共3组。结果,关于血清尿酸值,“诱导食物组”慢慢上升,而“诱导食物+SCP组”维持2mg/ml左右的值,所以在试验开始29天以后,相对于“诱导食物组”,“诱导食物+SCP组”血清尿酸值显著变低(p<0.001)。另外,“诱导食物→诱导食物+SCP组”在转换饲料后,血清尿酸值变得平稳,饲料转换约10天后,相对于“诱导食物组”,“诱导食物→诱导食物+SCP组”血清尿酸值显著变低(p<0.01)。其结果如图1及图2所示。
实验例3
驯化饲养结束后,给予4周龄Wister雄性大鼠(n=6,共60只)下述饲料喂养:Oriental酵母株式会社生产的Oriental配合饲料中含有总量的3质量%的诱导高尿酸血症的氧嗪酸钾盐的饲料(诱导食物),或该饲料(诱导食物)中进一步含有总量的2.5质量%的来自鲨鱼、鲑、牛或鸡的硫酸软骨素蛋白复合物(SCP、来自鲑的SCP、来自牛的SCP、来自鸡的SCP:均为Maruha株式会社生产)的饲料(10~17.5g/天),,跟踪血清尿酸值的变化。结果,4种“诱导+SCP”组在摄取饲料第28天,血清尿酸值比“诱导食物”组显著降低(p<0.05)。其结果如图3所示。
由上述实验例的结果判断,硫酸软骨素蛋白复合物具有降低血清尿酸值的作用。
下面是本发明的高尿酸血症治疗或预防用组合物及含有该组合物的食品的实施例。
实施例1
利用下述[原材料],使用常用的片剂辅料,按常用方法,制备本发明的高尿酸血症治疗或预防用组合物的片剂。
[原材料]
·硫酸软骨素蛋白复合物 150mg
(SCP:Maruha株式会社生产)
·胶原肽 50mg
·谷物提取物 50mg
·维生素B2 0.06mg
·维生素C 5mg
·乳糖 200mg
·纤维素 49.89mg
关于得到的片剂的分析试验结果如下述表2所示。另外,分析试验方法根据财团法人日本健康·营养食品协会健康的辅助食品规格基准的试验方法。后述分析试验结果的试验方法也相同。
[表2]
分析试验项目 | 结果 | 注 |
核黄素(维生素B2) | 11.3mg/100g | - |
总抗坏血酸(总维生素C) | 1.21g/100g | 1 |
粘多糖·蛋白的含量 | 39.5质量% | 2 |
硫酸软骨素的确认 | 限度内 | 2 |
根据分析试验成绩书第102032302-001号及第102032302-001号-另附(均为平成14年3月29日日本食品分析中心发行)的结果计算。
注1:用酰肼衍生化后测定。
注2:根据日本健康·营养食品协会规格基准“含有粘多糖·蛋白食品”的试验方法进行试验。
另外,实施例1中使用的硫酸软骨素蛋白复合物(SCP:Maruha株式会社生产)的分析试验结果如下述表3所示。
[表3]
分析试验项目 | 结果 |
粘多糖含量 | 24.3质量%(注3) |
蛋白质含量 | 40.9质量% |
重金属含量 | 20ppm以下 |
砷含量 | 2ppm以下 |
一般生菌数 | 1.0×103以下 |
大肠杆菌群 | 阴性 |
注3:用硫酸钡重量法测定。
实施例2
利用下述[原材料],使用常用的片剂辅料,按常用方法,制备本发明的高尿酸血症治疗或预防用组合物的片剂。
[原材料]
·与实施例1所用相同的硫酸软骨素蛋白复合物 150mg
(SCP:Maruha株式会社生产)
·乳糖 137.9mg
·维生素C 0.1mg
·香料 2mg
·甜菊糖(stevia) 10mg
关于得到的片剂的分析试验结果如下述表4所示。
[表4]
分析试验项目 | 结果 | 注 |
粘多糖·蛋白的含量 | 41.6质量% | 4 |
硫酸软骨素的确认 | 限度内 | 4 |
硫酸软骨素与蛋白质比率的确认 | 0.5 | 4 |
一粒的重量 | 0.298g | - |
根据分析试验成绩书第102030514-005号及第102030514-006号(均为平成14年3月19日日本食品分析中心发行)的结果及一粒的重量计算。
注4:根据日本健康·营养食品协会规格基准“粘多糖·蛋白含有食品”的试验方法进行试验。
实施例3
利用下述[原材料],按常用方法,制作主食面包。
[原材料]
·硫酸软骨素蛋白复合物 1g
·强力粉 248.37g
·干酵母 3g
·食盐 5g
·砂糖 10g
·脱脂牛奶 3g
·奶油 10g
实施例4
利用下述[原材料],按常用方法,制作汤。
[原材料]
·硫酸软骨素蛋白复合物 1g
·甜玉米 250.0g
·奶油 30g
·洋葱 20g
·小麦粉 15g
·牛奶 200ml
·食盐 1.5g
·胡椒 0.1g
·砂糖 1g
·大蒜 5mg
·芹菜 5mg
·月桂 1mg
·谷氨酸钠 0.1g
·肌苷酸钠 0.01g
实施例5
利用下述[原材料],按常用方法,制作干馏咖喱(retort curry)。
[原材料]
·硫酸软骨素蛋白复合物 12.5g
·胡萝卜 100g
·土豆 300g
·洋葱 200g
·牛肉 300g
·咖喱粉 5g
·小麦粉 30g
·食盐 5g
·胡椒 1g
·砂糖 0.1g
·谷氨酸钠 1g
产业上的利用范围
本发明的效果在于提供具有降低血清尿酸值的作用,特别是使治疗痛风、预防及减少痛风发作的新的方法成为可能的新型高尿酸血症治疗或预防用组合物。
Claims (10)
1、高尿酸血症治疗或预防用组合物,其含有硫酸软骨素蛋白复合物作为有效成分。
2、权利要求1所述的组合物,其中硫酸软骨素蛋白复合物来自软骨鱼类。
3、权利要求1所述的组合物,其中硫酸软骨素蛋白复合物来自硬骨鱼类。
4、权利要求1所述的组合物,其中硫酸软骨素蛋白复合物来自哺乳类或鸟类。
5、权利要求1所述的组合物,其中硫酸软骨素蛋白复合物来自爬虫类、两栖类、甲壳类或软体动物。
6、权利要求1~5之任一项所述的组合物,其中硫酸软骨素蛋白复合物通过精制动物软骨的蛋白酶消化物得到。
7、权利要求1~5之任一项所述的组合物,其中硫酸软骨素蛋白复合物通过精制动物软骨的热水提取物或酸分解物得到。
8、权利要求1所述的组合物,其被制成使每天摄取硫酸软骨素蛋白复合物达10mg~5g的范围的制剂。
9、权利要求1所述的组合物,其为痛风的治疗或预防用组合物。
10、含有硫酸软骨素蛋白复合物的食品,其特征是添加权利要求1所述的组合物,使硫酸软骨素蛋白复合物的含量达到10mg~5g的范围。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002145285A JP2003335698A (ja) | 2002-05-20 | 2002-05-20 | 高尿酸血症治療又は予防用組成物 |
JP145285/2002 | 2002-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1655810A true CN1655810A (zh) | 2005-08-17 |
Family
ID=29545079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA03811691XA Pending CN1655810A (zh) | 2002-05-20 | 2003-05-16 | 高尿酸血症治疗或预防用组合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050222010A1 (zh) |
EP (1) | EP1506785B1 (zh) |
JP (1) | JP2003335698A (zh) |
KR (1) | KR20050010819A (zh) |
CN (1) | CN1655810A (zh) |
CA (1) | CA2486313A1 (zh) |
WO (1) | WO2003097081A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102077933A (zh) * | 2010-09-20 | 2011-06-01 | 王强 | 一种高尿酸患者专用的海洋特膳食品 |
CN103446175A (zh) * | 2013-09-03 | 2013-12-18 | 中国海洋大学 | 水溶性氨基糖在制备治疗高尿酸血症、痛风、肾病的药物和保健品中的应用 |
CN103719990A (zh) * | 2013-12-17 | 2014-04-16 | 浙江现代中药与天然药物研究院有限公司 | 一种含有螺旋藻和鲣鱼骨提取物的功能性饮料 |
CN110547466A (zh) * | 2019-09-25 | 2019-12-10 | 浙江海洋大学 | 一种功能性鱿鱼软骨低聚糖泡腾片及其制备方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4834671B2 (ja) * | 2005-09-29 | 2011-12-14 | 株式会社マルハニチロ水産 | 成人病の予防及び治療に有効な組成物 |
CN101230369B (zh) * | 2007-01-25 | 2011-02-09 | 浙江海洋学院 | 软骨素的提取方法 |
WO2012070905A2 (ko) * | 2010-11-26 | 2012-05-31 | Kim Young-Moon | 인체의 희귀 난치성 질환 예방 및 치료용 연체동물 추출물 |
CN104661537A (zh) * | 2012-09-27 | 2015-05-27 | 三得利控股株式会社 | 皮肤状态改善剂 |
JP5992065B2 (ja) * | 2015-04-02 | 2016-09-14 | サンスター株式会社 | アスコルビン酸及びその類縁体を安定配合した組成物 |
CN105709207A (zh) * | 2016-01-29 | 2016-06-29 | 徐宝贞 | 一种用于治疗痛风的药物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0571597A4 (en) * | 1991-11-15 | 1994-06-01 | Arthro Res & Dev Corp | Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals |
JP3248170B2 (ja) * | 1992-12-11 | 2002-01-21 | マルハ株式会社 | コンドロイチン硫酸蛋白複合体含有食品 |
JP3693359B2 (ja) * | 1993-07-21 | 2005-09-07 | マルハ株式会社 | 骨強化促進剤 |
JPH07308169A (ja) * | 1994-05-16 | 1995-11-28 | Haputo Internatl:Kk | 加工食品用配合剤 |
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
FR2791262B1 (fr) | 1999-03-22 | 2001-09-28 | Virbac Sa | Compositions a base de chondroitine et de chitosan pour la protection, le traitement ou le remplacement des tissus conjonctifs |
JP4034024B2 (ja) * | 2000-02-22 | 2008-01-16 | 株式会社日本バリアフリー | 機能性食品 |
WO2001085182A2 (en) * | 2000-05-12 | 2001-11-15 | Ferrosan As | Combined cartilage and plant extract compositions |
-
2002
- 2002-05-20 JP JP2002145285A patent/JP2003335698A/ja active Pending
-
2003
- 2003-05-16 EP EP03752913A patent/EP1506785B1/en not_active Expired - Lifetime
- 2003-05-16 US US10/514,732 patent/US20050222010A1/en not_active Abandoned
- 2003-05-16 CN CNA03811691XA patent/CN1655810A/zh active Pending
- 2003-05-16 KR KR10-2004-7018649A patent/KR20050010819A/ko not_active Application Discontinuation
- 2003-05-16 CA CA002486313A patent/CA2486313A1/en not_active Abandoned
- 2003-05-16 WO PCT/JP2003/006140 patent/WO2003097081A1/ja active Application Filing
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102077933A (zh) * | 2010-09-20 | 2011-06-01 | 王强 | 一种高尿酸患者专用的海洋特膳食品 |
CN102077933B (zh) * | 2010-09-20 | 2013-04-24 | 王强 | 一种高尿酸患者专用的海洋特膳食品 |
CN103446175A (zh) * | 2013-09-03 | 2013-12-18 | 中国海洋大学 | 水溶性氨基糖在制备治疗高尿酸血症、痛风、肾病的药物和保健品中的应用 |
CN103719990A (zh) * | 2013-12-17 | 2014-04-16 | 浙江现代中药与天然药物研究院有限公司 | 一种含有螺旋藻和鲣鱼骨提取物的功能性饮料 |
CN103719990B (zh) * | 2013-12-17 | 2018-10-12 | 浙江现代中药与天然药物研究院有限公司 | 一种含有螺旋藻和鲣鱼骨提取物的功能性饮料 |
CN110547466A (zh) * | 2019-09-25 | 2019-12-10 | 浙江海洋大学 | 一种功能性鱿鱼软骨低聚糖泡腾片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2486313A1 (en) | 2003-11-27 |
WO2003097081A1 (fr) | 2003-11-27 |
EP1506785A4 (en) | 2009-07-29 |
EP1506785A1 (en) | 2005-02-16 |
EP1506785B1 (en) | 2013-04-03 |
JP2003335698A (ja) | 2003-11-25 |
US20050222010A1 (en) | 2005-10-06 |
KR20050010819A (ko) | 2005-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101834640B1 (ko) | 기능성 노견죽 및 그 제조방법 | |
CN107467462A (zh) | 一种有助于减肥的代餐固体饮料及其制备方法 | |
CN101057643A (zh) | 降糖大米 | |
CN1708236A (zh) | 普鲁兰作为慢消化碳水化合物的用途 | |
CN1655810A (zh) | 高尿酸血症治疗或预防用组合物 | |
CN108208802A (zh) | 一种适合糖尿病患者食用的特殊膳食及其制备方法 | |
CN105079028A (zh) | 一种改善骨关节的保健品及其制备方法 | |
Cordova-Torres et al. | Effect of water deprivation and increasing levels of spineless cactus (Nopalea cochenillifera) cladodes in the diet of growing lambs on intake, growth performance and ruminal and intestinal morphometric changes | |
CN1764463A (zh) | 降低血中低分子量含氮化合物浓度的改善病情用食品 | |
CN1493208A (zh) | 一种膳食纤维冲食粉 | |
CN1813794A (zh) | 排铅助长片及其制备方法 | |
CN1231255C (zh) | 以南瓜为主要原料制备的治疗便秘的胶囊配方及配制方法 | |
JP2009051775A (ja) | 持久力増強剤および抗疲労剤 | |
CN108208813A (zh) | 一种具有保健作用的减肥消脂片及其制备方法 | |
CN1209978C (zh) | 核酸补充营养保健食品及其制作方法 | |
CN1225175C (zh) | 降糖牛奶及其制造方法 | |
CN1286503C (zh) | 一种具有降低血糖、血脂作用的中药组合物及其制备方法 | |
JP2007117014A (ja) | 関節リウマチ症予防のための栄養補助食品 | |
CN102105160A (zh) | 用于增加血清抗氧化剂浓度的组合物和方法 | |
JP4249976B2 (ja) | そば粉及びその製造方法並びにその用途 | |
KR20050039013A (ko) | 솔잎과 마늘에 의한 오리 사육방법 및 그 오리고기 | |
CN113812378B (zh) | 一种食蟹猴肥胖症模型的建立方法及其应用 | |
CN1714653A (zh) | 一种面包及其制备方法 | |
CN106573034B (zh) | 海洋肽和鱼核苷酸、组合物及其用于降低血糖的用途 | |
CN1868289A (zh) | 降糖牛奶及其制造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: Tokyo, Japan, Japan Applicant after: Maruha Riru Corp. Address before: Tokyo, Japan, Japan Applicant before: Japan Maru Hari Shandong Fisheries |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MARUHA RIRU FISHERIES JAPAN CO., LTD. TO: MARUHA RIRU CORP. |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20050817 |